Brainomix e-Lung AI Imaging Technology Selected as Co-Primary Endpoint in Boehringer Ingelheim Phase 3 Clinical Trial in Pulmonary Fibrosis

The DROP-FPF trial is the first Phase 3 trial in interstitial lung disease (ILD) to use automated, quantitative high-resolution CT scan (HRCT) imaging biomarkers as a co-primary endpoint. Brainomix's e-Lung software has been selected by Boehringer Ingelheim to provide these AI-derived imaging biomarkers, marking a major milestone in ILD trial design.